MNX Market Network Exchange
Commercial intelligence · New York
Menu
MarketAwardsContracts and grants already awardedOpportunitiesRFPs and grants open nowPolicyBills, laws, and regulationsProgramsNamed funding initiatives and who they fundCalendarUpcoming committee hearings and meetings
NetworkOfficialsEveryone holding public office in New York City and StateOrganizationsPublic and civic sector organizations across New YorkLobbyingWho is registered to lobby, for which client, and for how much
ExchangeMarket structureWho funds a sector, how concentrated it is, and who is establishedStakeholder mapThe offices whose remit intersects your work, mapped to your siteLobbying landscapeWho is already lobbying your space, the most-lobbied offices, and what representation costsDossiersOne reconciled file on any organization, agency, or officialMonitorAlerts on new money, RFPs, and mentions you trackBuild a PlanA strategic plan customized for you
AboutHire a consultant ↗
Sign inGet Pro
Build my strategy
$1,000The New York strategy we build for retained clients, made accessible.Build my strategy →

New York funding

Phase II randomized controlled trial of benfotiamine in early Alzheimer's Disease

$8.5M

ShareLinkedIn ↗Email
Funder
National Institute on Aging
Amount
$8.5M
Recipient
Weill Medical Coll Of Cornell Univ
Deadline
Through June 30, 2028

Purpose

National Institute on Aging awarded $8.5M to Weill Medical Coll Of Cornell Univ (PI Howard Feldman) for Phase II randomized controlled trial of benfotiamine in early Alzheimer's Disease. Biomedical and health research. Location: NY.

federalnihgranthealthny

Official source ↗

Free account

Create a free account

Track New York funding and save searches across the Network. Free. No card required.

Want to reach the funders and organizations active in your market? Build your Market Network Strategic Plan →

Phase II randomized controlled trial of benfotiamine in early Alzheimer's Disease ($8.5M) | New York funding tracker